化疗所致血小板减少症治疗的研究进展

doi:10.11904/j.issn.1002-3070.2016.02.020

Abstract

Abstract: Chemotherapy induced thrombocytopenia(CIT)is a major dose-limiting hematologic toxicity with cancer patients.Aside from bleeding risk,thrombocytopenia limits chemotherapy doses and frequencies.While platelet transfusion is remain the elementary method for CIT,administration of platelet growth factors,such as recombinant human interleukin-11(rhIL-11),recombinant human thrombopoietin(rhTPO)and thrombopoietin receptor agonist(TPO-RA),are convenient and effective platelet-support strategies for patients receiving myelosuppressive chemotherapy.In addition,other cytokines and proximal splenic artery embolization(PSAE)are expected to be new clinical therapies.In this review,we summarize the existing data and approaches in the treatment progress of CIT.

Key words: Chemotherapy, Thrombocytopenia, Treatment

CLC Number:

R733.7

SUN Guoqiang, SUN Lichun. Treatment progress of chemotherapy induced thrombocytopenia[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 184-188.

References

1 Ten Berg MJ,van den Bemt PM,Shantakumar S,et al.Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy:results from a retrospective hospital-based cohort study[J].Drug Saf,2011,34(12):1151-1160.
2 Piatek C,Akhtari M.Thrombocytopenia:optimizing approaches in cancer patients[J].Oncology(Williston Park),2015,29(4):297-298.
3 Chinese Society of Clinical Oncology.Expert consensus on diagnosis and treatment of chemotherapy-induced thrombocytopenia in cancer patients(2014 version)[J].Zhonghua Zhong Liu Za Zhi,2014,36(11):876-879.
4 Hitron A,Steinke D,Sutphin S,et al.Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors[J].J Oncol Pharm Pract,2011,17(4):312-319.
5 Tanriverdi O.Association of helicobacter pylori infection with chemotherapy-induced thrombocytopenia in patients with stage III colon cancer:a pilot study[J].Platelets,2014,25(2):118-124.
6 Tanriverdi O.Is there a predictive significance of ABO blood group on chemotherapy-induced thrombocytopenia in patients with stage III colon cancer?[J].Med Oncol,2015,32(1):384-391.
7 Stanworth SJ,Estcourt LJ,Powter G,et al.A no-prophylaxis platelet-transfusion strategy for hematologic cancers[J].N Engl J Med,2013,368(19):1771-1780.
8 Crighton GL,Estcourt LJ,Wood EM,et al.A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation[J].Cochrane Database Syst Rev,2015,25(9):343-349.
9 Wandt H,Schaefer-Eckart K,Wendelin K,et al.Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies:an open-label,multicentre,randomised study[J].Lancet,2012,380(9850):1309-1316.
10 Kumar A,Mhaskar R,Grossman BJ,et al.Platelet transfusion:a systematic review of the clinical evidence[J].Transfusion,2015,55(5):1116-1127.
11 Nahirniak S,Slichter SJ,Tanael S,et al.Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia[J].Transfus Med Rev,2015,29(1):3-13.
12 Estcourt LJ,Stanworth SJ,Doree C,et al.Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation[J].Cochrane Database Syst Rev,2015,26(11):423-431.
13 Stanworth SJ,Hudson CL,Estcourt LJ,et al.Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies:recurrent event analysis[J].Haematologica,2015,100(6):740-747.
14 Slichter SJ,Kaufman RM,Assmann SF,et al.Dose of prophylactic platelet transfusions and prevention of hemorrhage[J].N Engl J Med,2010,362(7):600-613.
15 Estcourt LJ,Stanworth S,Doree C,et al.Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation[J].Cochrane Database Syst Rev,2015,32(10):632-642.
16 Kaushansky K.Use of thrombopoietic growth factors in acute leukemia[J].Leukemia,2000,14(3):505-508.
17 Tepler I,Elias L,Smith JW,et al.A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy[J].Blood,1996,87(9):3607-3614.
18 Jung Y,Ahn H,Kim DS,et al.Improvement of biological and pharmacokinetic features of human interleukin-11 by site-directed mutagenesis[J].Biochem Biophys Res Commun,2011,405(3):399-404.
19 Wu SK,Zhang Y,Xu LY,et al.Multicenter,randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy[J].Support Care Cancer,2012,20(8):1875-1884.
20 Dams-Kozlowska H,Kwiatkowska-Borowczyk E,Gryska K,et al.Designer cytokine hyper interleukin 11(H11)is a megakaryopoietic factor[J].Int J Med Sci,2013,10(9):1157-1165.
21 Li JZ,Yang C,Xia YP,et al.Thrombocytopenia caused by the development of antibodies to thrombopoietin[J].Blood,2001,98(12):3241-3248.
22 Kuter DJ.Managing thrombocytopenia associated with cancer chemotherapy[J].Oncology(Williston Park),2015,29(4):282-294.
23 Vadhan-Raj S,Verschraegen CF,Bueso-Ramos C,et al.Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer[J].Ann Intern Med,2000,132(5):364-368.
24 Erickson-Miller CL,Pillarisetti K,Kirchner J,et al.Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast,lung,and ovarian tumors[J].BMC Cancer,2012,12:405.
25 Parameswaran R,Lunning M,Mantha S,et al.Romiplostim for management of chemotherapy-induced thrombocytopenia[J].Support Care Cancer,2014,22(5):1217-1222.
26 Demeter J,Istenes I,Fodor A,et al.Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia(CIT)in a patient with mantle cell lymphoma[J].Pathol Oncol Res,2011,17(1):141-143.
27 Berthelot-Richer M,Boilard B,Morin A,et al.Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia[J].Transfusion,2012,52(4):739-741.
28 Winer ES,Safran H,Karaszewska B,et al.Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors:a randomized phase I study[J].Cancer Med,2015,4(1):16-26.
29 García Lagunar MH,Cerezuela Fuentes P,Martínez Penella M,et al.Experience of off-label use of eltrombopag in the treatment of thrombocytopenia associated with solid tumors[J].Farm Hosp,2015,39(3):157-160.
30 Ghanima W,Lee SY,Barsam S,et al.Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists[J].Br J Haematol,2012,158(6):811-814.
31 Moulis G,Bagheri H,Sailler L,et al.Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009-2013 French PharmacoVigilance assessment[J].Eur J Intern Med,2014,25(8):777-780.
32 Mitchell WB,Bussel JB.Thrombopoietin receptor agonists:a critical review[J].Semin Hematol,2015,52(1):46-52.
33 Holl P,Lisá L,Plameňová I,et al.Recombinant activated factor VII as an additional agent in the management of bleeding in patients with chemotherapy-induced thrombocytopenia[J].Blood Transfus,2013,11(3):466-468.
34 Zhan L,Zhang YL,Feng Z,et al.Recombinant human tyrosyl-tRNA synthetase,a novel thrombopoietic agent[J].Eur J Pharmacol,2014,738(6):293-300.
35 Bhatia SS,Venkat S,Echenique A,et al.Proximal splenic artery embolization in chemotherapy-induced thrombocytopenia:a retrospective analysis of 13 patients[J].J Vasc Interv Radiol,2015,26(8):1205-1211.

[1]	LIANG Hong, LI Qi, WANG Yaoxian, JIN Hong, WANG Tong, WANG Yanan, DUAN Yani, SONG Min. Interrupted time series trial for prevention of cardiovascular toxicity induced by chemotherapy in cervical cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 134-138.
[2]	MA Zhijie, WANG Fan, ZHAO Yashuang. Analysis of life quality and influencing factors in breast cancer patients with chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 149-154.
[3]	QIN Lanqun, ZOU Zhengyun. Progress in chemotherapy for malignant melanoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 167-172.
[4]	FANG Lin, LIU Chao, ZHANG Chunhui, ZHANG Yanqiao. Research status and treatment strategies of maintenance therapy for metastatic colorectal cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 173-178.
[5]	CHANG Xiaoxia, SONG Bingbing, LIU Jiaren. Research progress in phytochemicals for increasing sensitivity of tumor cells to chemotherapies [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 67-72.
[6]	XING Zhichao, MAI Wei. Research progress on potential targets of liposarcoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 82-86.
[7]	TIAN Yang, WU Huaxing. Clinical application of ultra-fine nasal endoscopy in digestive tract stenosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 550-554.
[8]	WANG Yuan, SUN Yihua. Advance in the role of β-catenin in soft tissue tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 455-459.
[9]	JIANG Liangliang, WANG Jing. Progress in diagnosis and treatment of distant metastasis of epithelial ovarian cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 480-482.
[10]	ZHANG Li,FANG Kewei,YUE Xi,WANG Hong,YANG Hanfeng,XU Xiaoxue. Research progress of cryoablation for bone metastases [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 353-356.
[11]	ZHANG Ting, JIA Di, YANG Dan. Progress in biological treatment of osteosarcoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 254-257.
[12]	LI Lin, LI Zhigao. The relationship between metformin and different molecular subtypes of breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 267-270.
[13]	ZHAI Keke, GAO Yuanyuan, FENG Xiao, XU Jingwen, GONG Yufang, MENG Qingwei. Analysis of first-line NSCLC chemotherapy in the phase Ⅳ patients with distant metastasis and first diagnosis after postoperative adjuvant chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 107-111.
[14]	YANG Wenjuan, YU Jing, HUANG Zhao, ZHANG Junhong, XIE Conghua. Correlation between the decline of severe granulocyte in the early stage of chemotherapy and the prognosis of small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 19-24.
[15]	LI Yujiao, SHANG Naijian. Research progress of imaging evaluation of neoadjuvant chemotherapy in breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 63-67.

Treatment progress of chemotherapy induced thrombocytopenia

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments